Evidence map›Paper›PMID 27751167›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2016

Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents:

Christopher I McHugh, Jawana M Lawhorn-Crews, Dipenkumar Modi, Kirk A Douglas, Steven K Jones, Thomas J Mangner, Jerry M Collins, Anthony F Shields

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Exploring Solvent Effects in the Radiosynthesis ofACS pharmacology & translational science · 2021
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Christopher I McHughCancer Biology Graduate Program, Wayne State University, Detroit, MI, 48201, USA.
Jawana M Lawhorn-CrewsKarmanos Cancer Institute and Oncology, Wayne State University, 4100 John R., HW04HO, Detroit, MI, 48201, USA.
Dipenkumar ModiKarmanos Cancer Institute and Oncology, Wayne State University, 4100 John R., HW04HO, Detroit, MI, 48201, USA.
Kirk A DouglasKarmanos Cancer Institute and Oncology, Wayne State University, 4100 John R., HW04HO, Detroit, MI, 48201, USA.
Steven K JonesCancer Biology Graduate Program, Wayne State University, Detroit, MI, 48201, USA.
Thomas J MangnerRadiology, Wayne State University, Detroit, MI, 48201, USA.
Jerry M CollinsNational Cancer Institute, Bethesda, MD, 20892, USA.
Anthony F ShieldsKarmanos Cancer Institute and Oncology, Wayne State University, 4100 John R., HW04HO, Detroit, MI, 48201, USA. shieldsa@karmanos.org.
Wayne State University · USThe Barbara Ann Karmanos Cancer Institute · USNational Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA principal goal for the use of positron emission tomography (PET) in oncology is for real-time evaluation of tumor response to chemotherapy. Given that many contemporary anti-neoplastic agents function by impairing cellular proliferation, it is of interest to develop imaging modalities to monitor these pathways. Here we examined the effect of capecitabine on the uptake of thymidine analogs used with PET: 3'-deoxy-3'-[

methodsFifteen patients were imaged, five with each imaging agent. Patients had been previously diagnosed with breast, colorectal, gastric, and esophageal cancers and had not received therapy for at least 4 weeks prior to the first scan, and had not been treated with any prior fluoropyrimidines. Subjects were imaged within a week before the start of capecitabine and on the second day of treatment, after the third dose of capecitabine. Tracer uptake was quantified by mean standard uptake value (SUV

resultsPatients imaged with

conclusionsThis pilot study demonstrates that patients treated with capecitabine can produce a marked increase in

Indexed as

Positron-Emission TomographyAdultAgedAntimetabolites, AntineoplasticArabinofuranosyluracilCapecitabineDideoxynucleosidesFemaleHumansMaleMiddle AgedNeoplasmsRadiopharmaceuticals1-(2'-deoxy-2'-fluoro-1-arabinofuranosyl)-5-uracilalovudineAntimetabolites, AntineoplasticArabinofuranosyluracilCapecitabineclevudineDideoxynucleosidesRadiopharmaceuticalsCapecitabineFAUFLTFMAUOncologyPET

Identifiers

PMID27751167
PMCPMC5067904
OpenAlexW2536182661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.